Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Operating expenses:
Research and development	$ 571	$ 1,394	$ 2,473	$ 4,549
General and administrative	2,533	2,070	6,725	6,171
Total operating expenses	3,104	3,464	9,198	10,720
Loss from operations	(3,104)	(3,464)	(9,198)	(10,720)
Interest income		3		14
Other expense	(9)		(93)
Loss before income taxes	(3,113)	(3,461)	(9,291)	(10,706)
Provision for income taxes	0	0	0	0
Net loss	(3,113)	(3,461)	(9,291)	(10,706)
Other comprehensive income (loss), net of tax		1	(4)	(10)
Comprehensive loss	$ (3,113)	$ (3,460)	$ (9,295)	$ (10,716)
Loss per share:
Net loss per share, basic	$ (3.50)	$ (4.66)	$ (10.45)	$ (14.58)
Net loss per share, diluted	$ (3.50)	$ (4.66)	$ (10.45)	$ (14.58)
Weighted average shares of common stock outstanding:
Basic	888,693	742,810	888,693	734,500
Diluted	888,693	742,810	888,693	734,500